Edition:
United States

Recro Pharma Inc (REPH.OQ)

REPH.OQ on NASDAQ Stock Exchange Capital Market

6.44USD
3:59pm EST
Change (% chg)

$-0.13 (-1.98%)
Prev Close
$6.57
Open
$6.47
Day's High
$6.55
Day's Low
$6.40
Volume
13,235
Avg. Vol
35,907
52-wk High
$13.05
52-wk Low
$4.78

Chart for

About

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product... (more)

Overall

Beta: -0.51
Market Cap(Mil.): $146.91
Shares Outstanding(Mil.): 21.48
Dividend: --
Yield (%): --

Financials

  REPH.OQ Industry Sector
P/E (TTM): -- 79.36 29.34
EPS (TTM): -2.76 -- --
ROI: -43.48 -0.30 13.58
ROE: -172.82 -2.98 15.11

Recro Pharma shares plummet after FDA rejects non-opioid pain shot

Recro Pharma's shares dropped more than 50 percent on Thursday after the U.S. Food and Drug Administration declined to approve the drugmaker's non-opioid shot IV meloxicam, saying the pain-relieving effect did not meet expectations.

May 24 2018

UPDATE 2-Recro Pharma shares plummet after FDA rejects non-opioid pain shot

* FDA says drug's pain-relieving effect did not meet expectations

May 24 2018

BRIEF-Recro Pharma Receives Complete Response Letter From FDA

* RECRO PHARMA RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA

May 24 2018

FDA declines to approve Recro Pharma's non-opioid pain shot

The U.S. Food and Drug Administration on Thursday declined to approve Recro Pharma's IV meloxicam noting the pain-relieving effect of the drug did not meet its expectations.

May 24 2018

Earnings vs. Estimates